Chemotherapy-associated steatohepatitis
Some drugs may induce hepatotoxic lesions, such as steatosis or steatohepatitis found in Non-Alcoholic Fatty Liver Disease (NAFLD). Among these drugs there are some anti-tumoral molecules, such as methotrexate, 5-fluorouracil, irinotecan, tamoxifen and l-asparaginase. The hepatotoxic phenotype devel...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-11-01
|
| Series: | Annals of Hepatology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268120300041 |
| _version_ | 1819014281852616704 |
|---|---|
| author | Lucy Meunier Dominique Larrey |
| author_facet | Lucy Meunier Dominique Larrey |
| author_sort | Lucy Meunier |
| collection | DOAJ |
| description | Some drugs may induce hepatotoxic lesions, such as steatosis or steatohepatitis found in Non-Alcoholic Fatty Liver Disease (NAFLD). Among these drugs there are some anti-tumoral molecules, such as methotrexate, 5-fluorouracil, irinotecan, tamoxifen and l-asparaginase. The hepatotoxic phenotype developed from treatment with such drugs is known as “CASH” for “Chemotherapy-induced Acute Steatohepatitis”. The mechanism of toxicity is essentially based on mitochondrial toxicity. These lesions are chronic and often reversible when the treatment is stopped. Contributing factors related to the patient, the disease or the treatment play a major role in the emergence of CASH. It is important to identify chemotherapies with steatosis or steatohepatitis as risk factors in order to improve control of the metabolic risk factors associated with the patient and to reinforce monitoring during treatment. In the particular context of neo-adjuvant chemotherapy for metastatic colorectal cancer, a short duration of chemotherapy and a few-weeks delay between chemotherapy and surgery could reduce postoperative morbidity and mortality. |
| first_indexed | 2024-12-21T02:13:21Z |
| format | Article |
| id | doaj.art-cd548e609170466a9993d573b59a4d60 |
| institution | Directory Open Access Journal |
| issn | 1665-2681 |
| language | English |
| last_indexed | 2024-12-21T02:13:21Z |
| publishDate | 2020-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Annals of Hepatology |
| spelling | doaj.art-cd548e609170466a9993d573b59a4d602022-12-21T19:19:19ZengElsevierAnnals of Hepatology1665-26812020-11-01196597601Chemotherapy-associated steatohepatitisLucy Meunier0Dominique Larrey1Service d’Hépato-gastroentérologie et Transplantation, France; Corresponding author at: Hôpital Saint Eloi, 80 Avenue Fliche, 34295 Montpellier Cedex 5, France.Service d’Hépato-gastroentérologie et Transplantation, France; INSERM 1183, FranceSome drugs may induce hepatotoxic lesions, such as steatosis or steatohepatitis found in Non-Alcoholic Fatty Liver Disease (NAFLD). Among these drugs there are some anti-tumoral molecules, such as methotrexate, 5-fluorouracil, irinotecan, tamoxifen and l-asparaginase. The hepatotoxic phenotype developed from treatment with such drugs is known as “CASH” for “Chemotherapy-induced Acute Steatohepatitis”. The mechanism of toxicity is essentially based on mitochondrial toxicity. These lesions are chronic and often reversible when the treatment is stopped. Contributing factors related to the patient, the disease or the treatment play a major role in the emergence of CASH. It is important to identify chemotherapies with steatosis or steatohepatitis as risk factors in order to improve control of the metabolic risk factors associated with the patient and to reinforce monitoring during treatment. In the particular context of neo-adjuvant chemotherapy for metastatic colorectal cancer, a short duration of chemotherapy and a few-weeks delay between chemotherapy and surgery could reduce postoperative morbidity and mortality.http://www.sciencedirect.com/science/article/pii/S1665268120300041Chemotherapy-associated steatohepatitis (CASH)ChemotherapyHepatotoxicitySteatosisSteatohepatitis |
| spellingShingle | Lucy Meunier Dominique Larrey Chemotherapy-associated steatohepatitis Annals of Hepatology Chemotherapy-associated steatohepatitis (CASH) Chemotherapy Hepatotoxicity Steatosis Steatohepatitis |
| title | Chemotherapy-associated steatohepatitis |
| title_full | Chemotherapy-associated steatohepatitis |
| title_fullStr | Chemotherapy-associated steatohepatitis |
| title_full_unstemmed | Chemotherapy-associated steatohepatitis |
| title_short | Chemotherapy-associated steatohepatitis |
| title_sort | chemotherapy associated steatohepatitis |
| topic | Chemotherapy-associated steatohepatitis (CASH) Chemotherapy Hepatotoxicity Steatosis Steatohepatitis |
| url | http://www.sciencedirect.com/science/article/pii/S1665268120300041 |
| work_keys_str_mv | AT lucymeunier chemotherapyassociatedsteatohepatitis AT dominiquelarrey chemotherapyassociatedsteatohepatitis |